Viral influenza vaccinations in pregnancy for improving maternal, neonatal and infant health outcomes

Viral influenza vaccine during pregnancy may reduce confirmed influenza among women and their babies compared to placebo.

Summary

A Cochrane review including 1 study with a total of 2116 women and 2049 neonates evaluated the impact of viral trivalent inactivated influenza vaccination during pregnancy in South-Africa. Vaccination was associated with a reduction in reverse-transcriptase–polymerase-chain-reaction (RT-PCR) confirmed influenza among infants (RR 0.51, 95% CI 0.30 to 0.88; 2049 infants) and women (RR 0.50, 95% CI 0.29 to 0.86; 2116 women). There was no clear difference between the viral influenza and placebo control group in terms of maternal death, infant death up to 175 days after birth (RR 0.71, 95% CI 0.37 to 1.37, moderate quality evidence), perinatal death (stillbirth and death in the first week of life) (RR 1.32, 95% CI 0.73 to 2.38, moderate quality evidence), or influenza-like illness in women or their babies.

Clinical comments

Date of latest search: 29 January 2015

Ədəbiyyat

1. Salam RA, Das JK, Dojo Soeandy C et al. Impact of Haemophilus influenzae type B (Hib) and viral influenza vaccinations in pregnancy for improving maternal, neonatal and infant health outcomes. Cochrane Database Syst Rev 2015;(6):CD009982.